Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

BeatMove device: could music be the key to better walking rehab?

NCT ID NCT06226844

Symptom relief Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether music therapy delivered by the BeatMove device can help people with leg artery disease walk farther during a 3-month outpatient walking program. Fifty-four participants will either get real music therapy or a sham version while doing 36 walking sessions. The main goal is to see if music boosts walking distance and helps patients stick with their rehab.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
music therapy (BeatMove device)
What this could lead to
If it works, this could offer a simple, enjoyable way to help people with leg artery disease walk farther and stick with their rehab.
What could go wrong
This is a small, early-stage trial with only 54 participants. The music therapy may not improve walking distance more than the sham version, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with stage II arterial obliteration of the lower limbs (Leriche and Fontaine classification) with exertional claudication * Systolic Pressure Index at the toe \< 0.7 but absolute value \> 30 mmHg * Steno-occlusive lesions on arterial Doppler ultrasound examination of the lower limbs * Patient on an optimised vasculoprotective medical treatment (statin, antiplatelet agent, ACE inhibitor/ARB II) * Patient who is a beneficiary or entitled beneficiary of a health insurance scheme * Patient able to understand, write and read French * Patient who has given free and informed consent Exclusion Criteria: * Patients using walking aids (cane, wheelchair) * Amputation * Patient with a walking perimeter \< 150 m * Hearing or visual impairment * Chronic ischaemia * Trophic disorders * Orthopaedic or vascular MI surgery planned within 3 months * Major cardiovascular co-morbidities (MI \< 3 months or unstable angina) * Pregnant, breast-feeding or parturient women * Patients under court protection, guardianship or curatorship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arterial disorder arteriosclerosis obliterans atherosclerosis limb ischemia Plaque, Atherosclerotic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artery disease Atheromatous Lower limb ischemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nîmes

    RECRUITING

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.